No results

Novo Holdings Completes Acquisition of Ellab

Novo Holdings Completes Acquisition of Ellab

In June 2023, Novo Holdings agreed to acquire Ellab from EQT Private Equity. The transaction has now been approved by all relevant authorities, and the acquisition is completed.


Anders Hedegaard has been appointed Chairperson based on his many years of experience within the life science industry. His roles have included being CEO of GN Store Nord and GN Hearing, President and CEO of Bavarian Nordic A/S and CEO of Rodenstock. He has also been Chair of the Board of ALK for several years.

Furthermore, Novo Holdings and The Lundbeck Foundation have entered into agreement on The Lundbeck Foundation acquiring a minority stake in Ellab, becoming part of the company’s ownership group together with Novo Holdings. The Lundbeck Foundation’s investment in Ellab is subject to relevant regulatory approvals.


CEO of Ellab A/S, Ludvig Enlund commented:

“We are thrilled to start working with Novo Holdings, The Lundbeck Foundation, and Anders Hedegaard to secure the continued growth of Ellab. Together with the other members of the management team and our employees, I look forward to realizing the long-term potential of Ellab for the benefit of consumers by ensuring accuracy and compliance in our clients’ biotech and pharmaceutical processes.

We believe that the new ownership and Board of Directors will be a great collaborator in continuing our efforts to provide innovative solutions to our clients, and build on the great Ellab culture of dedication and commitment to consumer safety.”


Reference is made to the press release from Novo Holdings and the Lundbeck Foundation.

For further information, please contact:
Jan Fledelius,
Vice President, Global HR & Communications,

Phone: +45 42460200

About Ellab

Headquartered in Hillerød, Denmark, Ellab provides mission-critical Validation- and Monitoring Solutions and Services used for measuring and documenting critical parameters such as temperature, pressure, and CO2 in mainly biotech and pharma processes. The Company serves all of the top 20 biotech companies and all of the top 40 pharma companies globally helping them ensure consumer safety and regulatory compliance while reducing time to market and the risk of product loss.

More info:

About Novo Holdings

Novo Holdings is a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, one of the world’s largest philanthropic enterprise foundations. Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novozymes A/S and manages an investment portfolio, with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seeds, Venture, Growth, and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development.

More info:

About the Lundbeck Foundation

The Lundbeck Foundation is a commercial foundation encompassing a comprehensive range of commercial and philanthropic activities – all united by its strong purpose: Bringing Discoveries to Lives. The Foundation is the long-term and engaged owner of several international pharmaceutical and healthcare companies – Lundbeck, Falck, and ALK – and an active investor in the financial markets, in Danish biotech companies, and in Danish research, which is supported through philanthropic grants to health science talents and research programs at Danish universities. The Foundation’s grants amount to more than DKK 500 million annually and primarily focus on the brain. This includes the world’s largest personal prize for neuroscience research: The Brain Prize.

More info:

Read more exciting news about Ellab’s journey

Do you have a question?

Do you have a question?